Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Variability in the effect of subcutaneously administered insulin represents a major challenge in insulin therapy where precise dosing is required in order to achieve targeted glucose levels. Since this variability is largely influenced by the absorption of insulin, a deeper understanding of the factors affecting the absorption of insulin from the subcutaneous tissue is necessary in order to improve glycaemic control and the long-term prognosis in people with diabetes. These factors can be related to either the insulin preparation, the injection site/patient, or the injection technique. This review highlights the factors affecting insulin absorption with special attention on the physiological factors at the injection site. In addition, it also provides a detailed description of the insulin absorption process and the various modifications to this process that have been utilized by the different insulin preparations available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377 · cited 5×
“The negatively charged GAGs and proteoglycans attract water molecules to form the gel-like phase of the ECM and control interstitial fluid content [17].”
BackgroundInfluentialNalysnyk, L., Hernandez‐Medina, M., & Krishnarajah, G. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01160.x · Cited by 343
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984) · Diabetes Care · doi:10.2337/diacare.7.2.188 · Cited by 341
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331 · cited 1×
“In comparison, the analogue insulin degludec, which will be introduced below, has a half-life of approximately 25 hours [88].”
BackgroundNew insulin delivery recommendations
Frid, A. H., Kreugel, G., Grassi, G., Halimi, S., Hicks, D., Hirsch, L. J., Smith, M. J., Wellhoener, R., Bode, B. W., Hirsch, I. B., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.010 · Cited by 286 · cited 10×
“Time before withdrawal Rapid withdrawal may result in loss of insulin and increased pharmacokinetic variability between injections [141] With use of insulin pens, patients should count to 10 after the plunger is fully depressed before removing the needle from the skin”
BackgroundMethodInfluentialMudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1501 · Cited by 276
Variability of Insulin Absorption and Insulin Action
Heinemann, L. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/152091502320798312 · Cited by 267
Galloway, J. A., Spradlin, C. T., Nelson, R. L., Wentworth, S. M., Davidson, J. A., & Swarner, J. L. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.366 · Cited by 226
Derraik, J. G. B., Rademaker, M., Cutfield, W. S., Pinto, T. E., Tregurtha, S., Faherty, A., Peart, J. M., Drury, P. L., & Hofman, P. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086637 · Cited by 129
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89
Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects
Bantle, J. P., Neal, L., & Frankamp, L. M. (1993) · Diabetes Care · doi:10.2337/diacare.16.12.1592 · Cited by 70
de la Peña, A., Seger, M., Soon, D., Scott, A. J., Reddy, S. R., Dobbins, M. A., Brown‐Augsburger, P., & Linnebjerg, H. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.221 · Cited by 67 · cited 3×
“The effect of concentration on insulin pharmacokinetics does not apply to all soluble insulin preparations, for example, the 200U insulin degludec and insulin lispro [103, 104].”
BackgroundGlucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0218-x · Cited by 42
Self-citationHompesch, M., Muchmore, D. B., Morrow, L., Ludington, E., & Vaughn, D. E. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0117 · Cited by 25
Seested, T., Havelund, S., Jonassen, I. B., Hoeg-Jensen, T., Pyke, C., Kapor, J., & Nishimura, E. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.07.413 · Cited by 5
Self-citation
Cited by
Rao, P., Jiang, S.-F., Kipnis, P., Patel, D. M., Katsnelson, S., Madani, S., & Liu, V. X. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6417 · Cited by 39
Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes
Hoogwerf, B. J., Pantalone, K. M., Basina, M., Jones, M. C., Grant, M., & Kendall, D. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.002 · Cited by 22
Aleppo, G., DeSalvo, D. J., Lauand, F., Huyett, L. M., Chang, A., Vienneau, T., & Ly, T. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01366-9 · Cited by 19
Cengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Codner, E., Ehtisham, S., Jarosz-Chobot, P., Mungai, L. N. W., Ng, S. M., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543169 · Cited by 17
Metadata
- Authors
- Gradel, A. K. J., Porsgaard, T., Lykkesfeldt, J., Seested, T., Gram-Nielsen, S., Kristensen, N. R., & Refsgaard, H. H. F.
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2018-07-04
- Volume
- 2018
- Pages
- 1-17
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W2810846480
- Cited by
- 202
- References
- 21
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.